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Abstract
Introduction: We investigated the status of estrogen receptor alpha (ERa), progesterone receptor (PR), and
epidermal growth factor receptor 2 (HER2) in primary tumor and in the corresponding brain metastases in a
consecutive series of breast cancer patients. Additionally, we studied factors potentially influencing conversion and
evaluated its association with survival.
Methods: The study group included 120 breast cancer patients. ERa, PR, and HER2 status in primary tumors and in
matched brain metastases was determined centrally by immunohistochemistry and/or fluorescence in situ
hybridization.
Results: Using the Allred score of ≥ 3 as a threshold, conversion of ERa and PR in brain metastases occurred in
29% of cases for both receptors, mostly from positive to negative. Conversion of HER2 occurred in 14% of patients
and was more balanced either way. Time to brain relapse and the use of chemotherapy or trastuzumab did not
influence conversion, whereas endocrine therapy induced conversion of ERa (P = 0.021) and PR (P = 0.001), mainly
towards their loss. Receptor conversion had no significant impact on survival.
Conclusions: Receptor conversion, particularly loss of hormone receptors, is a common event in brain metastases
from breast cancer, and endocrine therapy may increase its incidence. Receptor conversion does not significantly
affect survival.
Introduction
The brain is a common site of relapse in breast cancer,
with an overall occurrence of 10% to 16% in historical
series [1]. The highest risk of brain relapse is associated
with triple negative and epidermal growth factor receptor
2 (HER2)-positive phenotypes, high tumor grade, and
specific molecular tumor signatures [2-4]. Within the last
several decades, the incidence of brain metastases in
breast cancer patients has been increasing, which has
been attributed to several factors, including the use of
novel cytotoxic agents [5,6], prolonged survival of
patients in an advanced stage, allowing more time for the
development of brain relapse, and the impact of targeted
systemic therapies [7].
HER2 status as well as expression of hormone recep-
tors (HRs) (that is, estrogen receptor (ER) and progester-
one receptor (PR)), are routinely determined in primary
breast cancers, and metastatic lesions have typically been
assumed to maintain the original phenotype. However,
several recent studies indicated a relatively large phenoty-
pic discordance between primary breast cancer and dis-
tant metastases. Receptor conversion seems to include
mainly loss of HRs [8-13], whereas HER2 alterations are
less common [4,8,9,12-16].
Brain metastases from breast cancer have traditionally
been managed with surgery or radiotherapy, and the
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phenotypes of these lesions have received little attention.
Even if systemic therapies were used, selection of treat-
ment was usually guided by the phenotype of the pri-
mary tumor. However, with the increasing role of
targeted systemic therapies, determination of brain
metastasis phenotype may have larger therapeutic
implications.
Most studies investigating changing phenotypes in
recurrent breast cancer have included various locations
of metastases, of which brain metastases constituted only
a minority. A few studies specifically addressing brain
metastases were relatively small or were restricted to
selected markers [4,17-22]. In consequence, the knowl-
edge on the conversion rate of HRs and HER2 in brain
metastases is limited, and the clinical implications of this
phenomenon remain unknown.
Here, we compared the status of ERa, PR, and HER2 in
primary tumors and in paired excised brain metastases in
a relatively large series of breast cancer patients, assessed
the impact of factors potentially influencing receptor
conversion, and evaluated association of particular phe-
notypic changes with survival.
Materials and methods
Patients
This multicenter study was approved by the institutional
review board of the coordinating center (Medical Univer-
sity of Gdansk, Poland). The archives of neurosurgery and
pathology departments were searched to identify eligible
patients. We used archival formalin-fixed paraffin-
embedded blocks, and all personal data were made anon-
ymous and coded; therefore patient consent was not
sought. Inclusion criteria included female sex and diagno-
sis of unilateral breast cancer with synchronous or meta-
chronous excised brain metastases. All forms of surgical
therapy to primary tumor, radiotherapy and systemic ther-
apy, before and after brain relapse, were allowed.
Demographic and clinicopathologic data, as well as
clinical follow-up, were extracted from institutional data-
bases or original patient files. The time to brain metas-
tases was calculated from the initial diagnosis of breast
cancer to excision of the metastatic lesion. Most brain
metastases were symptomatic, but some cases were
detected accidentally.
All formalin-fixed paraffin-embedded tissue blocks were
centrally collected, and new sections were cut and routi-
nely stained (hematoxylin-eosin, H&E). H&E-stained slides
were reviewed by a board-certified pathologist (WB) to
confirm the diagnosis of invasive breast cancer.
Immunohistochemistry staining and fluorescence in situ
hybridization analysis
All samples from primary tumor and from brain metas-
tases were restained, and immunohistochemistry
(IHC)-based expression for ERa, PR, and HER2 was deter-
mined in the central laboratory by a pathologist (WB) who
was blinded to original assessments and to expression in
the paired samples. In patients with more than one brain
metastasis, only the single most representative lesion was
subjected to receptor analysis.
Expression of ERa and PR was evaluated in the auto-
mated stainer (AutostainerLINK 48; DAKO, Glostrup,
Denmark) with the use of clone SP1 (DAKO) and clone
636 (DAKO) antibodies, respectively. Signals were
detected by EnVision FLEX kit. Expression of HRs was
scored by using the semiquantitative Allred system,
which takes into account the proportion of positive cells
(graded 0 to 5) and staining intensity (graded 0 to 3) [23].
The proportion of positive cells and intensity were then
summed to produce total scores of 0 or 2 through 8. A
score of 0 or 2 was regarded as negative, whereas a score
of 3 to 8, as positive. A positive result of either ERa or
PR classified the case as HR-positive. In additional ana-
lyses, the currently recommended more-stringent criteria
for HR positivity (≥ 1% staining) were used [24].
HER2 protein expression was determined by using
semiquantitative IHC with HER-2/neu Test (clone 4B5;
Ventana Medical Systems, Inc., Tucson, AZ, USA) and
ultraVIEW Universal DAB detection kit (Ventana) in an
automated stainer (Benchmark XT; Ventana). Samples
with strong, complete, homogeneous membrane staining
in > 30% of tumor cells (scored 3+) were considered posi-
tive, irrespective of the HER2 gene copy number deter-
mined with fluorescence in situ hybridization (FISH).
The samples showing intermediate expression (scored 2
+) were subjected to additional analysis of HER2 gene
copy number by using FISH. FISH testing was also per-
formed on brain metastatic lesions with conversion to
HER2 3+ determined with IHC. Gene amplification with
FISH was defined as a FISH ratio (HER2/centromeric
probe for chromosome 17 ratio) of greater than or equal
to 2.0. All FISH-positive patients were considered HER2-
positive.
For all receptors, results were considered concordant
if primary and metastatic tumor were both positive or
both negative by using the previously mentioned criteria,
whereas other combinations were considered discordant.
Statistical analysis
The status of HRs and HER2 of metastatic brain tumors
was compared with that of matched primary tumors and
presented as discordance rate, its 95% confidence interval
(CI), and the Cohen kappa statistics. The level of agree-
ment based on  values was assessed by using the Landis
and Koch criteria: 0.00 to 0.20, slight agreement; 0.21 to
0.40, fair agreement; 0.41 to 0.60, moderate agreement;
0.61 to 0.80, substantial agreement; and 0.81 to 1.00,
almost perfect agreement [25].
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The proportions between paired groups were compared
by using a c2 test or Fisher Exact test when appropriate.
Overall survival, calculated from the date of breast cancer
diagnosis to the date of death or last follow-up, was com-
puted by using the Kaplan-Meier method. Survival curves
were compared by using the log-rank test. Hazard ratios
(HRs) with 95% confidence intervals (95% CIs) were com-
puted by using Cox regression models. For all analyses, a
statistical significance level of 0.05 was used, with no
adjustment for multiple testing. All calculations were per-
formed with SPSS 13.0 (SPSS Inc., Chicago, IL, USA).
Results
The study group included 120 breast cancer patients trea-
ted in eight Polish institutions between 1996 and 2011
(Table 1). The median follow-up for the entire group was
97 months (range, 6 to 176 months). All patients under-
went surgery for primary breast cancer and for brain
metastases. The most frequent pathologic type was inva-
sive ductal carcinoma (82%), and 47% of the tumors were
grade 3. ERa, PR, and HER2 in primary tumors were posi-
tive in 42%, 34%, and 47% of patients, respectively. The
analyses using ≥ 1% staining as a criterion of HR positivity
showed virtually the same results and were not presented,
as in the entire group, only one patient had to be reclassi-
fied (from ERa negativity to ERa positivity). In total, 29%
of tumors were triple-negative. Almost all brain metastases
(97.5%) were metachronous (that is, appearing > 2 months
after the diagnosis of breast cancer had been rendered). In
60% of patients, brain was the first distant site of relapse.
The vast majority of patients had either unifocal (61%) or
two to three brain lesions (30%). Cerebellum was the most



















Not determined 1 1
HER2
Positive (IHC3+) 51 42
Positive (IHC2+ and FISH+) 6 5
Negative 62 52
Not determined 1 1
Chemotherapy before brain metastases
Yes, adjuvant, neoadjuvant 47 39
Yes, for metastatic disease 9 7
Yes, a combination thereof 47 39
Table 1 Patient characteristicsa (Continued)
No 8 7
Unknown 9 7
Endocrine therapy before brain metastasesb
Yes, adjuvant, neoadjuvant 31 26
Yes, for metastatic disease 5 4
Yes, a combination thereof 13 11
No 66 55
Unknown 5 4












Anti-HER2 therapy after brain surgeryc
Trastuzumab 9 16
Lapatinib 7 12
Sequentially both 3 5




Combined local regional and/or distant 1 1
Unknown 1 2
Dominant site of metastatic diseased




Age at breast cancer diagnosis (mean (range) years) 49 (26-80)
Age at brain metastasis surgery (mean (range) years) 52 (29-83)
aPercentages may not sum to 100 because of rounding to full numbers;
btamoxifen, aromatase inhibitors, or tamoxifen and aromatase inhibitors; cin
HER2-positive patients (IHC3+ or IHC2+ and FISH+); dcategory of worst
prognosis irrespective of the extent, in order: soft tissue, bone, visceral; see
Materials and methods. Number of patients, 120. ER, estrogen receptor; HER2,
epidermal growth factor receptor; PR, progesterone receptor; WBRT, whole-
brain radiotherapy.
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common site of brain metastases (27%), followed by parie-
tal and frontal lobes (19% each). Most patients received
chemotherapy, and more than 40% received endocrine
therapy in the (neo)adjuvant or metastatic settings before
brain surgery. Fifty-three percent of HER2-positive
patients received trastuzumab in one of these settings.
Conversion of HR status mostly included loss of recep-
tor expression in brain metastases by originally positive
breast carcinoma (Table 2). Conversion of ERa status
occurred in 35 (29% (95% CI, 21% to 38%);  = 0.389) of
120 patients, including 22 (43%) of 51 patients who lost
original expression in metastatic foci and 13 (19%) of 69
patients who acquired it (P = 0.005) (Figure 1). PR status
changed in 34 (29% (21% to 38%);  = 0.320) of 119
patients; in 23 (56%) of 41 patients from positive to nega-
tive, and in 11 (14%) of 78 patients from negative to posi-
tive (P < 0.001). The subsets of tumors with ERa and PR
conversions overlapped partially (22 (63%) of 35 tumors
with ERa conversion showed also PR conversion).
Conversion of HER2, considering IHC and FISH,
occurred in 17 (14%; 95% CI, 9% to 23%];  = 0.464) of
119 patients; in seven (12%) of 58 patients from positive
to negative, and in 10 (16%) of 61 patients from negative
to positive (P = 0.60). Interestingly, among nine patients
with IHC HER2 conversion to 3+ who were assessable
with FISH, only three proved to have underlying HER2
gene amplification. The number of cases with FISH
measurement in the primary tumor and in the corre-
sponding brain metastases was too small for meaningful
analysis.
No relation was found between the changes of HRs
and HER2 (P = 1.0).
Because more than 80% of patients received che-
motherapy before brain metastases, its impact on con-
version cannot be reliably assessed. Trastuzumab did
not significantly affect conversion of HER2 (change in
two of 31 patients versus four of 28 patients not admi-
nistered trastuzumab; P = 0.22), whereas endocrine ther-
apy strongly influenced conversion of both HRs (ER, 20
of 49 and 13 of 66 in patients who did and did not
receive endocrine therapy, respectively; P = 0.021; PR,
22 of 48 and 10 of 66, respectively; 0.001). Most ER and
PR conversions after endocrine therapy were toward the
loss of both HRs (85% and 82% of all conversions,
respectively).
Finally, the conversion rate of any receptor did not
associate with time from primary diagnosis to brain sur-
gery considered as a continuous variable (P = 0.64, 0.91,
and 0.87, for ERa, PR, and HER2, respectively).
The median overall survival from primary diagnosis in
the entire group was 4.7 years (95% CI, 3.3 to 6.1), and
5-year survival was 48% (95% CI, 38% to 57%).
Patients who were ERa or PR negative in the primary
tumors and retained their negativity in their brain
metastases did significantly worse than the other
patients (ERa, log-rank P = 0.005; HR = 1.84 (95% CI,
1.20 to 2.83]; PR, P = 0.005; HR, 1.89 (95% CI, 1.22 to
2.94)), but no apparent impact of ERa and PR conver-
sion was found either way on survival (Figures 2 and 3).
Similarly, no prognostic impact of HER2 conversion was
found (Figure 4).
After the brain surgery (missing data excluded), 80%
of patients received whole-brain radiotherapy, 55%, che-
motherapy, 20%, endocrine therapy, and 25% of HER2-
positive patients based on primary tumor assessment
received anti-HER2 therapy (trastuzumab, lapatinib, or
sequentially both), including three patients who received
lapatinib based on HER2 gain in the brain lesion. In
some patients, receptor status in brain metastases was
not determined right after the excision (exact number
unknown), so no attempt was made to evaluate the
impact of conversion on subsequent systemic therapy.
Discussion
We performed comprehensive analyses of ERa, PR, and
HER2 expression in primary tumors and in paired brain
metastases in a large series of breast cancer patients. As
expected, two phenotypes of primary tumor, HER2-posi-
tive and triple negative, were clearly overrepresented in
this series (47% and 29%, respectively), as both are asso-
ciated with a particularly high risk of brain relapse [1-4].
Additionally, almost half of primary tumors were poorly
differentiated, and only a few low-grade tumors were
found.
Our study demonstrated a relatively high rate of HR
conversion in brain metastases from breast cancer.
Table 2 Paired analysis of receptor expression in breast
cancer and brain metastases
Brain metastasis
Primary tumor Negative Positive Total number
(%)
ER Negative, n (%) 56 (81) 13 (19) 69 (100)
Positive, n (%) 22 (43) 29 (57) 51 (100)
Total, n (%) 78 (65) 42 (35) 120 (100)
Overall discordance rate
(95% CI)
29% (21% to 38%)
PR Negative, n (%) 67 (85) 11 (15) 78 (100)
Positive, n (%) 23 (56) 18 (44) 41 (100)
Total, n (%) 90 (76) 29 (24) 119 (100)
Overall discordance rate
(95% CI)
29% (21% to 38%)
HER2 Negative, n (%) 51 (84) 10 (16) 61 (100)
Positive, n (%) 7 (12) 51 (88) 58 (100)
Total, n (%) 58 (49) 61 (53) 119 (100)
Overall discordance rate
(95% CI)
14% (9% to 22%)
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A switch of ERa and PR (29% each) was within the wide
range of conversions reported earlier for other sites of
relapse [8-11,26,27].
HR conversion in the brain has not been studied
extensively, as in most studies, the brain constituted
only a small fraction of all metastatic sites. A few small
Figure 1 Phenotypes for ER (A), PR (B), and HER2 (C) in primary tumors and their matched brain metastases. ER, estrogen receptor; PR,
progesterone receptor; HER2, epidermal growth factor receptor 2.
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studies (23 to 44 patients) specifically addressing brain
metastases showed a broad range (6% to 44%) of HR
conversion [4,17-21]. None of these studies was large
enough for meaningful analysis of factors influencing
conversion and related prognosis.
Similar to that of other metastatic sites [9,10,12,28],
conversion of ERa and PR in brain metastases in our
series resulted mainly in loss of ERa and PR (63% and
68% of all conversions, respectively). This phenomenon
is likely a result of tumor heterogeneity and the develop-
ment of brain metastases from a minority of cells pre-
sent within the primary tumor, as shown in a recent
study using next-generation sequencing technologies
[29]. Less-likely causes include clonal selection of undif-
ferentiated HR-negative tumor cells from an original
heterogeneous population of tumor cells during endo-
crine therapy, or silencing of HR expression due to acti-
vation of growth-factor signaling [30,31].
Some studies have suggested that HR discordance, in
particular toward loss of HRs in metastatic sites, is related
to shorter survival [12,13,32], which might have been due
to inappropriate therapy or to selection of treatment-
resistant tumor clones with unstable and more aggressive
phenotypes. We were unable to confirm this finding; how-
ever, relatively few patients presented with HR-positive
primary tumor, and our analysis was thus underpowered.
A few patients in our series demonstrated gain of HRs, a
finding that may support a repeated measurement, prefer-
ably including retesting of primary tumors.
In our study, HER2 status in brain metastases was less
prone to changes compared with HRs, and conversions
in both directions were more balanced. The overall con-
version rate of 14% is close to a pooled HER2 discor-
dance rate of 11.5% for distant metastases at various
locations demonstrated in a recent systematic review of
26 studies [14]. We did not find any clinical factors
influencing HER2 conversion. In the previously men-
tioned review, metachronous (versus synchronous)
occurrence of metastases was the only factor increasing
the HER2 conversion rate. A recent study including 182
patients demonstrated a conversion rate of HER2 in
24% of metastases, and this phenomenon was correlated
with preceding chemotherapy and not with trastuzumab
therapy [33].
Figure 2 Overall survival in relation to ERa conversions. Log-rank P = 0.041 (all comparisons); P = 0.005 (ER-/ER- versus others); HR = 1.84
(1.20 to 2.83; ER-/ER- versus others).
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HER2 conversion in brain metastases was reported in
a few studies, and the results seem to be similar com-
pared with other metastatic sites [4,8-22]. However, all
these studies were relatively small (up to 44 patients)
[9]; thus any comparisons should be interpreted with
caution. Interestingly, one small study suggested a full
concordance of HER2 status in brain metastases deter-
mined with FISH, as opposed to IHC assessment [22].
Nevertheless, we verified FISH status in all patients with
positive HER2 IHC expression in the brain lesions, and
indeed, the proportion of FISH-positive cases among
otherwise IHC HER2-positive cases seemed to be lower
compared with respective figures in primary tumors.
This finding may be related to heterogeneity of primary
tumors or to specific features of the brain microenviron-
ment [34,35]. The question of biologic behavior of
HER2 IHC-positive, FISH-negative metastatic brain
tumors and particularly their responsiveness to anti-
HER2 therapy remains to be established. Similar to that
of HRs, conversion of HER2 did not apparently influ-
ence survival, and no clinical factors were associated
with this phenomenon.
Discordant phenotypes in primary and recurrent
breast cancers have usually been interpreted as a genu-
ine switch in tumor biology or intratumoral heterogene-
ity, with treatment-related selection of more-aggressive
and resistant clones [36,37]. An apparent loss of HRs in
patients administered endocrine therapy in this series
seems to support strongly the latter hypothesis. How-
ever, some differences may also be due to limited accu-
racy and reproducibility of receptor assays and to
sampling errors related to focal intratumor heterogene-
ity, and the relative contributions of all these factors are
unknown [38]. Notably, a study using gene expression
and genomic hybridization techniques suggests relative
genomic stability of breast cancer over time [39],
although this may not apply to brain metastases [40].
Possible differences in preanalytic procedures (such as
tissue handling before fixation, quality and length of fixa-
tion), immunostaining and interpretation of results are
particularly important in retrospective multiinstitutional
studies on tissue tumor markers. In our study, the assess-
ments were made centrally on newly prepared immunos-
tained sections and in a blinded manner, minimizing the
Figure 3 Overall survival in relation to progesterone receptor (PR) conversions. Log-rank P = 0.037 (all comparisons); P = 0.005 (PR-/PR-
versus others); HR = 1.89 (1.22 to 2.94; PR-/PR- versus others).
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risk of analytic discordance and interobserver variability.
By using full tissue sections, we also decreased the impact
of intratumoral heterogeneity and problems with the
reliability of biomarker expression in small biopsy speci-
mens [41]. However, our results should still be inter-
preted with caution, as we were unable to control for
preanalytic procedures and to assess their impact.
The most important question related to changing
tumor phenotypes in metastatic lesions is the clinical
relevance of these events. A relatively high discordance
rate may suggest the clinical utility of repeated immu-
nostaining of recurrent lesions, because currently used
systemic therapies of advanced breast cancer are widely
dependent on the appropriate targeting of HRs and
HER2. At least three prospective studies demonstrated a
change of clinical management in 14% to 20% of breast
cancer patients as a result of discordance between pri-
mary and metastatic tumors [26-28]. The reevaluation
of metastatic breast cancer lesions is now recommended
by the European Society of Medical Oncology and the
American Society of Clinical Oncology [42,43]; however,
no particular recommendations were made in relation
to brain metastases. Specific features of brain metastases
include their low accessibility for a biopsy and a limited
blood-brain barrier penetrance for most cytotoxic agents
and trastuzumab. The array of effective systemic thera-
pies in breast cancer brain metastases may, however,
soon be expanded by emerging targeted agents. For
example, a recent phase II study demonstrated an
impressive volumetric response rate of 67% (29 of 43
patients) with a combination of lapatinib and capecita-
bine in radiotherapy-naïve brain metastases in HER2-
positive breast cancer [44].
In our series, in all cases, brain metastasis samples
were obtained at surgical excision, allowing subsequent
analysis. Nevertheless, in some patients, immediate
receptor measurement in brain lesions was not per-
formed locally, and its impact on clinical decisions
could not be reliably assessed. The results of our study
cannot also be extrapolated to inoperable brain metas-
tases, and the relevance of biopsy attempts in such cases
remains unknown. Rationally, this decision should be
based mainly on clinical judgment, and a biopsy consid-
ered, if its results would affect clinical decision making,
or if a possibility exists of unrelated disease (second pri-
mary tumor or benign lesion). However, the biopsy
Figure 4 Overall survival in relation to epidermal growth factor receptor 2 (HER2) conversions. Log-rank P = 0.944 (all comparisons); P =
0.582 (PR-/PR- versus others); HR = 1.13 (0.73 to 1.74; HER2-/HER2- versus others).
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attempt should be balanced, owing to technical difficul-
ties of obtaining accessible tissue from the brain lesion
and to patient reluctance. In the case of discordant
results, a retesting of primary tumor by using the same
methods should be considered.
Conclusions
Our study demonstrates that, in a proportion of breast
cancer patients, the receptor phenotype of brain metas-
tases does not reflect its status in primary tumor. This
might suggest that missing this discordance, particularly in
the case of receptor gain, may deny some patients a poten-
tially effective systemic therapy. However, a verification of
this assumption in a prospective clinical trial including a
random patient assignment to therapy based on the
assessment of metastatic versus primary lesions does not
seem feasible. Nevertheless, available data suggest that in
routine clinical practice, repeated immunostaining of
excised brain metastases seems to be worthwhile. The
biopsy of an inoperable brain lesion should be weighed
against technical difficulties and the risk of such proce-
dure, and should always be a joint decision between the
patient and physician.
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